Sana Biotechnology, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
Sana Biotechnology, Inc. (SANA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 771.00 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2026-08-10
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-06-30 was 299.00K shares, a 76.62% decline year-over-year.
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-03-31 was 472.00K shares, a 87.14% decline year-over-year.
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-12-31 was 621.00K shares, a 82.53% decline year-over-year.
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-09-30 was 1.58M shares, a 4.87% decline year-over-year.
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2025 was 7.15M shares, a 2.33% increase from fiscal 2024.
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2024 was 6.99M shares, a 69.38% increase from fiscal 2023.
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2023 was 4.13M shares, a 9.10% decline from fiscal 2022.
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2022 was 4.54M shares, a 393.80% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 299.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | 771.00K shares 10-Q · filed 2026-08-10 | 1.39M shares derived: sum of 3 quarters · filed 2026-08-10 | 2.97M shares derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | 472.00K shares 10-Q · filed 2026-05-11 | 1.09M shares derived: sum of 2 quarters · filed 2026-05-11 | 2.67M shares derived: sum of 3 quarters · filed 2026-05-11 | 3.95M shares derived: sum of 4 quarters · filed 2026-05-11 |
| 2025-12-31 | 621.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | 2.20M shares derived: sum of 2 quarters · filed 2026-03-03 | 3.48M shares derived: sum of 3 quarters · filed 2026-03-03 | 7.15M shares 10-K · filed 2026-03-03 |
| 2025-09-30 | 1.58M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 2.86M shares derived: sum of 2 quarters · filed 2025-11-06 | 6.53M shares 10-Q · filed 2025-11-06 | 10.08M shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 1.28M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | 4.95M shares 10-Q · filed 2025-08-11 | 8.50M shares derived: sum of 3 quarters · filed 2025-08-11 | 10.16M shares derived: sum of 4 quarters · filed 2025-08-11 |
| 2025-03-31 | 3.67M shares 10-Q · filed 2025-05-08 | 7.22M shares derived: sum of 2 quarters · filed 2025-05-08 | 8.89M shares derived: sum of 3 quarters · filed 2025-05-08 | 9.61M shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 3.56M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | 5.22M shares derived: sum of 2 quarters · filed 2025-03-17 | 5.94M shares derived: sum of 3 quarters · filed 2025-03-17 | 6.99M shares 10-K · filed 2025-03-17 |
| 2024-09-30 | 1.66M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | 2.38M shares derived: sum of 2 quarters · filed 2024-11-08 | 3.43M shares 10-Q · filed 2024-11-08 | 5.79M shares derived: sum of 4 quarters · filed 2024-11-08 |
| 2024-06-30 | 722.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 1.77M shares 10-Q · filed 2024-08-08 | 4.13M shares derived: sum of 3 quarters · filed 2024-08-08 | 5.14M shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 1.05M shares 10-Q · filed 2024-05-08 | 3.40M shares derived: sum of 2 quarters · filed 2024-05-08 | 4.41M shares derived: sum of 3 quarters · filed 2024-05-08 | 4.85M shares derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-12-31 | 2.36M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | 3.37M shares derived: sum of 2 quarters · filed 2024-02-29 | 3.81M shares derived: sum of 3 quarters · filed 2024-02-29 | 4.13M shares 10-K · filed 2024-02-29 |
| 2023-09-30 | 1.01M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | 1.45M shares derived: sum of 2 quarters · filed 2023-11-08 | 1.77M shares 10-Q · filed 2023-11-08 | 4.12M shares derived: sum of 4 quarters · filed 2023-11-08 |
| 2023-06-30 | 440.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | 759.00K shares 10-Q · filed 2023-08-03 | 3.11M shares derived: sum of 3 quarters · filed 2023-08-03 | 4.33M shares derived: sum of 4 quarters · filed 2023-08-03 |
| 2023-03-31 | 319.00K shares 10-Q · filed 2023-05-08 | 2.67M shares derived: sum of 2 quarters · filed 2023-05-08 | 3.89M shares derived: sum of 3 quarters · filed 2023-05-08 | 4.59M shares derived: sum of 4 quarters · filed 2023-05-08 |
| 2022-12-31 | 2.35M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | 3.57M shares derived: sum of 2 quarters · filed 2023-03-16 | 4.27M shares derived: sum of 3 quarters · filed 2023-03-16 | 4.54M shares 10-K · filed 2023-03-16 |
| 2022-09-30 | 1.22M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | 1.92M shares derived: sum of 2 quarters · filed 2022-11-02 | 2.19M shares 10-Q · filed 2022-11-02 | 2.44M shares derived: sum of 4 quarters · filed 2022-11-02 |
| 2022-06-30 | 700.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | 970.00K shares 10-Q · filed 2022-08-04 | 1.22M shares derived: sum of 3 quarters · filed 2022-08-04 | 1.51M shares derived: sum of 4 quarters · filed 2022-08-04 |
| 2022-03-31 | 270.00K shares 10-Q · filed 2022-05-10 | 518.00K shares derived: sum of 2 quarters · filed 2022-05-10 | 813.00K shares derived: sum of 3 quarters · filed 2022-05-10 | 972.00K shares derived: sum of 4 quarters · filed 2022-05-10 |
| 2021-12-31 | 248.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16 | 543.00K shares derived: sum of 2 quarters · filed 2022-03-16 | 702.00K shares derived: sum of 3 quarters · filed 2022-03-16 | 919.00K shares 10-K · filed 2022-03-16 |
| 2021-09-30 | 295.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | 454.00K shares derived: sum of 2 quarters · filed 2021-11-08 | 671.00K shares 10-Q · filed 2021-11-08 | |
| 2021-06-30 | 159.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | 376.00K shares 10-Q · filed 2021-08-04 | ||
| 2021-03-31 | 217.00K shares 10-Q · filed 2021-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |